Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
1(20%)
Results Posted
50%(1 trials)
Terminated
2(40%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_1
3
60%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (75.0%)
N/A1 (25.0%)

Trials by Status

recruiting120%
completed240%
terminated240%

Recent Activity

1 active trials
Showing 5 of 5
recruiting

Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

NCT02161783
completednot_applicable

MIBG for Refractory Neuroblastoma and Pheochromocytoma

NCT01850888
terminatedphase_1

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

NCT01372228
completedphase_1

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
terminatedphase_1

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

NCT00579111

Clinical Trials (5)

Showing 5 of 5 trials
NCT02161783

Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

Recruiting
NCT01850888Not Applicable

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Completed
NCT01372228Phase 1

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

Terminated
NCT02167958Phase 1

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Completed
NCT00579111Phase 1

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Terminated

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5